Gilead Sciences falls after quarterly sales miss estimates
View all comments(0)
Shares of drugmaker Gilead Sciences GILD.O fall 3.4% to $102.59 in extended trading
Company reports Q1 sales of $6.67 bln, below analysts' estimates of $6.81 bln, according to data compiled by LSEG
Sales of company's cancer drug, Trodelvy, fell 5% to $293 mln
Sales of company's COVID-19 antiviral, Veklury, fell 45% to $302 mln
However, company reports Q1 adj. profit of $1.81/shr, above analysts' estimates of $1.79/shr
As of last close, stock up 14.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.